Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1698306 | 0.83 | L3MBTL1 (0.44) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL11053483 | 0.82 | MEN1 (0.51) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL18535093 | 0.76 | L3MBTL1 (0.43) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL4320007 | 0.76 | ALDH1A1 (0.45) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL6908084 | 0.76 | MEN1 (0.44) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL11213326 | 0.74 | KDM4E (0.41) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL9064055 | 0.74 | ALDH1A1 (0.46) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL11601893 | 0.73 | L3MBTL1 (0.42) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL6905835 | 0.72 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1GAAMAPT | |
| Phosphine SCHEMBL28030392 | 0.72 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030013896-A1 | Pyrone derivatives and method for producing same | LONZA AG (CH) | 2003-01-16 | — | — | US | claimed |
| US-6716999-B2 | REACTING 4-HALOACETOACETYL HALIDE IN A SOLVENT AND SCANDIUM TRIFLUOROMETHANESULFONATE (A LEWIS ACID) AND THEN HYDROLYZED TO FORM PYRONE DERIVATIVE | LONZA AG (CH) | 2004-04-06 | — | — | US | disclosed |
| US-20030013896-A1 | Pyrone derivatives and method for producing same | LONZA AG (CH) | 2003-01-16 | — | — | US | disclosed |
| EP-1254138-A1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | Novartis AG (CH) | 2002-11-06 | — | — | EP | disclosed |
| EP-1235821-A2 | PYRONE DERIVATIVES AND A METHOD FOR PRODUCING SAME | Lonza AG (CH) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001058899-A1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | NOVARTIS AG (CH) | 2001-08-16 | — | — | WO | disclosed |
| WO-2001040212-A2 | PYRONE DERIVATIVES AND A METHOD FOR PRODUCING SAME | LONZA AG (CH) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013896-A1 | Pyrone derivatives and method for producing same | XDH, AMY1A, CA1 | MEN1 293/4885KMT2A 1155/4885ALDH1A1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.